{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49,
    50,
    52,
    53,
    54,
    70,
    74,
    75,
    76
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_llm_1",
        "definition": "Randomisation",
        "anchorType": "Randomization",
        "timelineId": null,
        "dayValue": 0,
        "sourceText": "Visit 2, Randomisation (Day 0)"
      },
      {
        "id": "anchor_1",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "informed consent"
      },
      {
        "id": "anchor_2",
        "definition": "Procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_3",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_26",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "Treatment period"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "sourceText": "Follow-up period"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P360D",
        "endOffset": "null",
        "interval": "P120D",
        "minObservations": 4,
        "exitCondition": "Study Closure Visit (SCV)",
        "sourceText": "Visit 7, 8, 9 etc (Day 360±14; and every 4th month ±14 days)"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "epoch_1",
          "epoch_2",
          "epoch_4",
          "epoch_5"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Day 1",
          "Visit 5 (Day 120)",
          "Visit 3 (Day 14)",
          "Visit 1 (Enrolment)",
          "Study Closure Visit",
          "Visit 6 (Day 240)",
          "Visit 7 (Day 360)",
          "Visit 4 (Day 60)",
          "End of Study",
          "Screening",
          "Visit 2 (Randomisation)"
        ],
        "sourceText": "[{'condition': 'If subject discontinues investigational product early', 'path': ['PREMATURE_TREATMENT_DISCONTINUATION_VISIT', 'MODIFIED_FOLLOW_UP']}, {'condition': 'If volume status requires adjustment', 'path': ['IP_DOSE_REDUCTION', 'IP_INTERRUPTION', 'IP_RESTART']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Concomitant \nMedication",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2; SINGLE signals: 2"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Dosing",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Mri",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Informed Consent Form (ICF) Signing",
        "executionType": "Single",
        "rationale": "Obtained once at the start of the study as part of screening/enrollment."
      },
      {
        "activityId": "Kansas City Cardiomyopathy Questionnaire (KCCQ)",
        "executionType": "Single",
        "rationale": "Total symptom score is assessed at multiple visits (e.g., Visit 2 and Visit 6) to evaluate changes over time."
      },
      {
        "activityId": "Adverse Event (AE) Collection",
        "executionType": "Single",
        "rationale": "Continuous monitoring and recording of events from the time of consent through the study closure visit."
      },
      {
        "activityId": "Investigational Product (IP) Dose Reduction/Interruption",
        "executionType": "Single",
        "rationale": "Conditional workflow based on the evaluation of volume status or acute worsening of heart failure."
      },
      {
        "activityId": "Echocardiographic Sub-study Assessments",
        "executionType": "Single",
        "rationale": "Scheduled procedures added to specific visits (Visit 2 and Visit 6) for sub-study participants."
      },
      {
        "activityId": "Concomitant Medication Recording",
        "executionType": "Single",
        "rationale": "Continuous recording of cardiovascular medications in the eCRF throughout the course of the study."
      },
      {
        "activityId": "Laboratory Testing (eGFR)",
        "executionType": "Single",
        "rationale": "Protocol-mandated laboratory values are systematically analyzed at scheduled intervals."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "timing_before",
        "text": "a. Local laboratory assessment is optional and may be used to assess eligibility (according to local routine) of NT-proBNP. If used, the ICF need to be signed before the optional assessment starts.",
        "footnoteId": "fn_1",
        "sourceText": "a. Local laboratory assessment is optional and may be used to assess eligibility (according to local"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "b. LV assessments should be done if no assessment has been performed within 12 months prior to enrolment, or if the results of prior assessments are unavailable.",
        "footnoteId": "fn_2",
        "sourceText": "b. LV assessments should be done if no assessment has been performed within 12 months prior to enrol"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_before",
        "text": "c. Only for patients in the echocardiography substudy: A baseline echocardiographic assessment will occur after eligibility is confirmed and prior to the randomization at visit 2. A follow up echocardiogram will occur at visit 6.",
        "footnoteId": "fn_3",
        "sourceText": "c. Only for patients in the echocardiography substudy: A baseline echocardiographic assessment will "
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "d. Central laboratory assessments include alkaline phosphatase (ALP), ALT, AST, bilirubin, blood urea nitrogen (BUN), creatinine (including eGFR assessment), haematocrit, haemoglobin (Hb), HbA1c, NT-proBNP, phosphate, potassium, and sodium, as specified in Table 2.",
        "footnoteId": "fn_4",
        "sourceText": "d. Central laboratory assessments include alkaline phosphatase (ALP), ALT, AST, bilirubin, blood ure"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "procedure_timepoints",
        "text": "e. PK samples will be collected at visit 7.",
        "footnoteId": "fn_5",
        "sourceText": "e. PK samples will be collected at visit 7."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_after",
        "text": "f. PGIS, KCCQ, EQ-5D-5L will be filled in at visit 2,5,6,7 and every 12 months after visit 7, and at PTDV and SCV. PGIC will be filled in at the same visits, with exception of visit 2.",
        "footnoteId": "fn_6",
        "sourceText": "f. PGIS, KCCQ, EQ-5D-5L will be filled in at visit 2,5,6,7 and every 12 months after visit 7, and at"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "g. SAEs will be collected from the time of informed consent throughout the study until and including the patient’s last visit. Potential endpoints, DAEs, AEs leading to dose reduction and temporary interruptions and AEs of interest will be collected from randomisation throughout the study until and including the patient’s last visit.",
        "footnoteId": "fn_7",
        "sourceText": "g. SAEs will be collected from the time of informed consent throughout the study until and including"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "h. IP Dispensation only",
        "footnoteId": "fn_8",
        "sourceText": "h. IP Dispensation only"
      },
      {
        "id": "fn_cond_9",
        "conditionType": "general",
        "text": "i. IP Collection only.",
        "footnoteId": "fn_9",
        "sourceText": "i. IP Collection only."
      },
      {
        "id": "fn_cond_10",
        "conditionType": "procedure_timepoints",
        "text": "j. Blood samples for potential future biomarker research will be collected at visit 2 and visit 7 and may be analysed at the discretion of AstraZeneca. The biomarker sampling is subject to separate approval/consent by the patient and is optional.",
        "footnoteId": "fn_10",
        "sourceText": "j. Blood samples for potential future biomarker research will be collected at visit 2 and visit 7 an"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: CV death or HF event",
        "endpointType": "Primary",
        "inputs": [
          "CV death date",
          "Hospitalisation for HF date",
          "Urgent HF visit date",
          "Randomisation date"
        ],
        "timeWindow": {
          "reference": "Randomisation",
          "duration": "Until Study End Date (SED)"
        },
        "algorithm": "min(date_CV_death, date_HF_hosp, date_urgent_HF_visit) - date_randomisation",
        "successCriteria": "Hazard Ratio < 1.0 (Superiority of dapagliflozin vs placebo)",
        "sourceText": "Time to the first occurrence of any of the components of this composite: 1. CV death 2. Hospitalisation for HF 3. An urgent HF visit"
      },
      {
        "id": "ep_2",
        "name": "Secondary: CV death or hospitalisation for HF",
        "endpointType": "Secondary",
        "inputs": [
          "CV death date",
          "Hospitalisation for HF date",
          "Randomisation date"
        ],
        "timeWindow": {
          "reference": "Randomisation",
          "duration": "Until Study End Date (SED)"
        },
        "algorithm": "min(date_CV_death, date_HF_hosp) - date_randomisation",
        "successCriteria": "Statistically significant reduction in hazard ratio",
        "sourceText": "Time to the first occurrence of any of the components of this composite: 1. CV death 2. Hospitalisation for HF"
      },
      {
        "id": "ep_3",
        "name": "Secondary: Recurrent HF hospitalisations and CV death",
        "endpointType": "Secondary",
        "inputs": [
          "Hospitalisation for HF count",
          "CV death occurrence"
        ],
        "timeWindow": {
          "reference": "Randomisation",
          "duration": "Until Study End Date (SED)"
        },
        "algorithm": "sum(HF_hospitalisations) + (1 if CV_death else 0)",
        "successCriteria": "Reduction in total number of events compared to placebo",
        "sourceText": "Total number of recurrent HF hospitalisations and CV death."
      },
      {
        "id": "ep_4",
        "name": "Secondary: KCCQ Total Symptom Score",
        "endpointType": "Secondary",
        "inputs": [
          "KCCQ score at baseline",
          "KCCQ score at 8 months"
        ],
        "timeWindow": {
          "reference": "Baseline",
          "duration": "P8M"
        },
        "algorithm": "KCCQ_score_8_months - KCCQ_score_baseline",
        "successCriteria": "Improvement in total symptom score vs placebo",
        "sourceText": "Change from baseline measured at 8 months in the total symptom score of the KCCQ"
      },
      {
        "id": "ep_5",
        "name": "Secondary: Worsening Renal Function Composite",
        "endpointType": "Secondary",
        "inputs": [
          "eGFR",
          "ESRD status",
          "Chronic dialysis status",
          "Renal transplant status",
          "Renal death date"
        ],
        "timeWindow": {
          "reference": "Randomisation",
          "duration": "Until Study End Date (SED)"
        },
        "algorithm": "min(date_50pct_eGFR_decline, date_ESRD, date_renal_death) - date_randomisation",
        "successCriteria": "Reduction in incidence vs placebo",
        "sourceText": "Time to the first occurrence of any of the components of this composite: 1. ≥50% sustained* decline in estimated glomerular filtration rate (eGFR) 2. Reaching End Stage Renal Disease... 3. Renal death"
      },
      {
        "id": "ep_6",
        "name": "Secondary: All-cause mortality",
        "endpointType": "Secondary",
        "inputs": [
          "Death date",
          "Randomisation date"
        ],
        "timeWindow": {
          "reference": "Randomisation",
          "duration": "Until Study End Date (SED)"
        },
        "algorithm": "date_death - date_randomisation",
        "successCriteria": "Reduction in incidence vs placebo",
        "sourceText": "Time to death from any cause."
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Time to first occurrence of CV death or HF event",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "CV death",
          "Hospitalisation for HF",
          "Urgent HF visit"
        ],
        "derivationRule": "min(date_of_cv_death, date_of_hHF, date_of_urgent_hf_visit) - date_of_randomization",
        "baselineDefinition": "Date of randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization to end of study",
        "imputationRule": "Censoring at last known date alive and event-free",
        "unit": "Days"
      },
      {
        "id": "dv_2",
        "name": "Time to first occurrence of CV death or hospitalisation for HF",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "CV death",
          "Hospitalisation for HF"
        ],
        "derivationRule": "min(date_of_cv_death, date_of_hHF) - date_of_randomization",
        "baselineDefinition": "Date of randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization to end of study",
        "imputationRule": "Censoring at last known date alive and event-free",
        "unit": "Days"
      },
      {
        "id": "dv_3",
        "name": "Total number of recurrent HF hospitalisations and CV death",
        "variableType": "Composite",
        "sourceVariables": [
          "HF hospitalisations",
          "CV death"
        ],
        "derivationRule": "Sum of all adjudicated HF hospitalisation events plus CV death event",
        "baselineDefinition": "Post-randomization events",
        "baselineVisit": "Day 1",
        "analysisWindow": "Entire study duration",
        "imputationRule": "Not specified",
        "unit": "Count"
      },
      {
        "id": "dv_4",
        "name": "Change from baseline in KCCQ total symptom score",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "KCCQ total symptom score"
        ],
        "derivationRule": "month8_value - baseline_value",
        "baselineDefinition": "Last non-missing value prior to randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "8 months",
        "imputationRule": "Not specified",
        "unit": "Score"
      },
      {
        "id": "dv_5",
        "name": "Change in body weight from baseline",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Body weight"
        ],
        "derivationRule": "post_baseline_value - baseline_value",
        "baselineDefinition": "Last non-missing value prior to randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "Not specified",
        "imputationRule": "Not specified",
        "unit": "kg"
      },
      {
        "id": "dv_6",
        "name": "Time to first fatal or non-fatal MI",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Myocardial infarction"
        ],
        "derivationRule": "date_of_first_mi - date_of_randomization",
        "baselineDefinition": "Date of randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization to end of study",
        "imputationRule": "Censoring",
        "unit": "Days"
      },
      {
        "id": "dv_7",
        "name": "Time to first fatal or non-fatal stroke",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Stroke"
        ],
        "derivationRule": "date_of_first_stroke - date_of_randomization",
        "baselineDefinition": "Date of randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "From randomization to end of study",
        "imputationRule": "Censoring",
        "unit": "Days"
      },
      {
        "id": "dv_8",
        "name": "eGFR decline >= 50% from baseline",
        "variableType": "Categorical",
        "sourceVariables": [
          "eGFR"
        ],
        "derivationRule": "If (baseline_eGFR - current_eGFR) / baseline_eGFR >= 0.50 then 'Yes' else 'No'",
        "baselineDefinition": "Last non-missing central lab value prior to randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "Entire study duration",
        "imputationRule": "Not specified",
        "unit": "Boolean"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Enrolment",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Enrolment",
        "Randomisation",
        "Premature treatment discontinuation visit (PTDV)",
        "Study closure visit (SCV)",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Enrolment",
          "toState": "Randomisation",
          "trigger": "Progress to Randomisation"
        },
        {
          "fromState": "Randomisation",
          "toState": "Premature treatment discontinuation visit (PTDV)",
          "trigger": "Progress to Premature treatment discontinuation visit (PTDV)"
        },
        {
          "fromState": "Premature treatment discontinuation visit (PTDV)",
          "toState": "Study closure visit (SCV)",
          "trigger": "Progress to Study closure visit (SCV)"
        },
        {
          "fromState": "Premature treatment discontinuation visit (PTDV)",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Enrolment": "epoch_1",
        "Randomisation": "epoch_2",
        "Premature treatment discontinuation visit (PTDV)": "epoch_4",
        "Study closure visit (SCV)": "epoch_5",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_llm_1",
        "treatmentName": "Dapagliflozin",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 10.0,
            "unit": "mg",
            "description": "investigational product dose"
          }
        ],
        "durationDescription": "Event-driven (estimated study period Q1 2017 to Q4 2019)",
        "doseModifications": [
          "Evaluation of volume status and investigational product (IP) dose reduction/interruption"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Placebo",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "Event-driven (estimated study period Q1 2017 to Q4 2019)",
        "doseModifications": [
          "Evaluation of volume status and investigational product (IP) dose reduction/interruption"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_15",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Enrolment period",
        "sourceText": "Investigator(s) should keep a record, the patient screening log, of patients who entered pre- study screening."
      },
      {
        "id": "visit_5",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "2.3 Safety objectives 6.3.1 Time period for collection of adverse events"
      },
      {
        "id": "visit_6",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "Treatment period",
        "sourceText": "Change from baseline measured at 8 months in the total symptom score of the KCCQ, a specific HF patient reported outcome questionnaire."
      },
      {
        "id": "visit_8",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "Visit 1, Enrolment (Day -14±7).......................................................................... 46 4.2 Treatment period........................................................................"
      },
      {
        "id": "visit_16",
        "visitName": "Visit 10",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "every 12 months thereafter, i.e., visit 10, 13 etc.  The investigator will perform a targeted physical examination with"
      },
      {
        "id": "visit_llm_None",
        "visitName": "Premature Treatment Discontinuation Visit (PTDV)",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 6,
        "epoch": "Treatment period"
      },
      {
        "id": "visit_llm_None",
        "visitName": "Study Closure Visit (SCV)",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Treatment period"
      },
      {
        "id": "visit_llm_None",
        "visitName": "Unscheduled visits",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 8,
        "epoch": "Treatment period"
      },
      {
        "id": "visit_9",
        "visitName": "Visit 3",
        "targetDay": 14,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "epoch": "Treatment period",
        "sourceText": "Visit 3 (Day 14±3) and Visit 4 (Day 60±7)......................................................... 48 4.2.3 Visit 5 (Day 120±7) ........................................................................"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Visit 4",
        "targetDay": 60,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 4,
        "targetWeek": 8.57,
        "epoch": "Treatment period"
      },
      {
        "id": "visit_11",
        "visitName": "Visit 5",
        "targetDay": 120,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "epoch": "Treatment period",
        "sourceText": "Visit 5 (Day 120±7) ........................................................................................... 48 4.2.4 Visit 6 (Day 240±14) .........................................................."
      },
      {
        "id": "visit_3",
        "visitName": "Visit 6",
        "targetDay": 240,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "epoch": "Treatment period",
        "sourceText": "4.2.4 Visit 6 (Day 240±14) Adding information related to the Echocardiographic Sub-study 2.3 Safety objectives"
      },
      {
        "id": "visit_13",
        "visitName": "Visit 7",
        "targetDay": 360,
        "windowBefore": 14,
        "windowAfter": 14,
        "isRequired": true,
        "visitNumber": 13,
        "epoch": "Treatment period",
        "sourceText": "Visit 7, 8, 9 etc (Day 360±14; and every 4th month ±14 days)............................. 50 4.2.6 Premature Treatment Discontinuation Visit (PTDV) .......................................... 50"
      },
      {
        "id": "visit_7",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 14,
        "sourceText": "Patient agrees to undergo modified follow-up .................................................... 40 3.10 Criteria for withdrawal......................................................................."
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified block randomization",
      "centralRandomization": true,
      "blockSize": "Not specified",
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "Type 2 Diabetes (T2D) status",
          "categories": [
            "With T2D (Established diagnosis OR HbA1c ≥ 6.5%)",
            "Without T2D"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Clinical Study Protocol\nDrug Substance Dapagliflozin\nStudy Code D1699C00001\nVersion 2.0\nDate 26 October 2017\n8 (102)\nTarget patient population\nThe target population includes male and female patients w"
    }
  }
}